Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Block Listing Six Monthly Return

30 Jun 2022 13:29

RNS Number : 8653Q
Diurnal Group PLC
30 June 2022
 

30 June 2022

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Block Listing Six Monthly Return

 

 

Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies, Diurnal Group plc makes the following update on its block listing:

 

Name of applicant:

Diurnal Group plc

Name of scheme:

Long Term Incentive Plan

Period of return:

From:

17 December 2021

To:

30 June 2022

Balance of unallotted securities under scheme(s) from previous return:

5,775,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

665,732

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,109,268

 

Name of contact:

Mike Scott

Telephone number of contact:

+44 (0)20 3727 1000

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Richard Bungay, Interim Chief Executive Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden

 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600

Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown

Corporate Broking: Nick Adams, Nick Harland

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

Vane Percy & Roberts (Medical Communications)

+44 (0) 173 782 1890

Simon Vane Percy

 

Notes to Editors

 

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREAAKEDAPAEFA
Date   Source Headline
7th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
7th Sep 20229:58 amRNSForm 8.5 (EPT/RI)
7th Sep 20229:23 amRNSMole Valley Asset Management Ltd-Form 8.3 Diurnal
6th Sep 20221:36 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
6th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
6th Sep 20229:04 amRNSForm 8.3 - [DIURNAL GROUP PLC]
5th Sep 20223:16 pmRNSForm 8.3 - Diurnal Group Plc
5th Sep 20221:36 pmRNSForm 8 (OPD) (Diurnal Group)
5th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
2nd Sep 20224:28 pmRNSForm 8 (OPD) (Neurocrine Biosciences, Inc.)
2nd Sep 20222:55 pmRNSForm 8.3 - Diurnal Group plc
2nd Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
2nd Sep 20228:58 amRNSForm 8.5 (EPT/RI)
1st Sep 20223:12 pmRNSForm 8.3 - Diurnal Group plc
1st Sep 20221:20 pmRNSForm 8.3 - Diurnal Group Plc
1st Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
1st Sep 202210:04 amRNSForm 8.5 (EPT/RI)
1st Sep 20229:38 amRNSForm 8.3 - [DIURNAL GROUP PLC]
1st Sep 20227:00 amRNSPostponement of R&D Day and Notice of Results
31st Aug 20223:20 pmRNSForm 8.3 - Diurnal Group plc
31st Aug 20222:03 pmRNSForm 8.3 - Diurnal Group PLC
31st Aug 202212:53 pmRNSForm 8.3 DIURNAL GROUP PLC
31st Aug 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
31st Aug 202211:56 amRNSForm 8.5 (EPT/RI) - Diurnal Group PLC
31st Aug 202211:55 amRNSForm 8.3 - Diurnal Group plc
31st Aug 202211:46 amGNWForm 8.3 - [Diurnal Group plc - 30 08 2022 - Opening Declaration] - (HHL)
31st Aug 20229:08 amRNSForm 8.3 - Diurnal Group PLC
30th Aug 202212:55 pmRNSForm 8.3 - DIURNAL GROUP PLC
30th Aug 202212:32 pmEQSForm 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc
30th Aug 20227:00 amRNSRECOMMENDED CASH ACQUISITION
26th Jul 20227:00 amRNSTrading Update
15th Jul 202212:04 pmRNSDirector Dealings
30th Jun 20221:29 pmRNSBlock Listing Six Monthly Return
7th Jun 20221:00 pmRNSDiurnal to present research at ENDO 2022
1st Jun 20227:00 amRNSFirst patient dosed in pivotal Phase 3 trial
23rd May 20228:41 amRNSCorrection: Presentation at ECE
23rd May 20227:00 amRNSPresentation at European Congress of Endocrinology
9th May 202212:49 pmRNSDirector Dealings
29th Apr 20223:37 pmRNSTotal Voting Rights
28th Apr 20227:00 amRNSDiurnal to present at Investor Evening
25th Apr 20227:00 amRNSDistribution agreement signed with EffRx
20th Apr 20227:00 amRNSDistribution agreement signed with Er-Kim
4th Apr 20227:00 amRNSDirectorate Change and Management Updates
1st Apr 20227:00 amRNSTotal Voting Rights
30th Mar 20227:00 amRNSDistribution agreement with Vector Pharma
22nd Mar 20224:35 pmRNSPrice Monitoring Extension
22nd Mar 20222:06 pmRNSSecond Price Monitoring Extn
22nd Mar 20222:00 pmRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSInterim Results
9th Mar 20227:00 amRNSInterim Results Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.